The magnitude of ORR improvement in HCC and dose-dependent response in MSS CRC suggests muzastotug has meaningful clinical differentiation. With recent capital raised via ATM (424B5), Adagene is funded to advance these programs. Traders should monitor for upcoming Phase 2 expansion data and potential partnership announcements, particularly with Roche (atezolizumab) or Merck (pembrolizumab).
Price Chart
Executive Summary
Adagene presented new clinical data at AACR 2026 showing strong efficacy for muzastotug in triple combination therapies: 66.7% ORR in HCC and dose-dependent 25-40% ORR in MSS CRC, with favorable safety. These results reinforce muzastotug's potential as a backbone immunotherapy and validate its masked CTLA-4 mechanism.
Key Facts
- In HCC, muzastotug + atezolizumab + bevacizumab achieved 66.7% ORR vs. 32.5% in control (n=6 vs n=40), with mPFS of 8.2 vs 5.5 months
- In MSS CRC, ORR was 25% at 10 mg/kg and 40% at 15 mg/kg of muzastotug in combination with pembrolizumab and fruquintinib (n=9 total)
- No Grade 4/5 TRAEs or DLTs observed; safety profile comparable to control arms
- Muzastotug administered at twice the dose of ipilimumab and continuously, demonstrating therapeutic index advantage
- FDA Fast Track designation already granted for muzastotug in combination with pembrolizumab for MSS mCRC
Financial Impact
Non-dilutive value inflection: robust clinical data de-risks development and increases probability of partnership or approval, potentially re-rating the $183M market cap biotech
Risk Factors
- Small sample sizes (n=6 and n=9) limit statistical power
- Interim data subject to change with longer follow-up
- Competition in HCC and MSS CRC combination immunotherapies is intense
- Execution risk in advancing to later-stage trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-044885 |
| Document: tm2611979d1_6k.htm | 0001104659-26-044885 |
| Document: 0001104659-26-044885-index-headers.html | 0001104659-26-044885 |
| Document: 0001104659-26-044885-index.html | 0001104659-26-044885 |
| Document: 0001104659-26-044885.txt | 0001104659-26-044885 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $3.20 | awaiting T+60 | — | $2.35 (−26.56%) |
Sep 22, 2026 4w ago | 6-K | $3.23 | awaiting T+60 | — | $2.35 (−27.24%) |
Sep 10, 2026 6w ago | 6-K | $3.31 | awaiting T+60 | — | $2.35 (−29.00%) |
Sep 9, 2026 6w ago | 6-K | $3.27 | awaiting T+60 | — | $2.35 (−28.13%) |
Aug 16, 2026 10w ago | Institutional Cluster | $3.83 | awaiting T+60 | — | $2.35 (−38.64%) |
Aug 12, 2026 10w ago | 6-K | $3.75 | awaiting T+60 | — | $2.35 (−37.33%) |
Aug 12, 2026 10w ago | Press Release | $3.75 | awaiting T+60 | — | $2.35 (−37.33%) |
Jul 6, 2026 16w ago | 6-K | $3.93 $3.21 | ▼ −18.32% | ▼ −20.04% | $2.35 (−40.20%) |
Apr 17, 2026 27w ago | 6-K | $3.89 $3.67 | ▼ −5.66% | ▼ −12.43% | $2.35 (−39.59%) |
Apr 2, 2026 29w ago | 6-K | $3.99 $4.20 | ▼ −5.26% | ▲ +8.90% | $2.35 (+41.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers